Can someone w an unbiased opinion please explain if Q scripts numbers is constantly10K per week why this is not considered doing well? Isn't Belviq's goal to also get scripts to 10K? I'm a long but just not clear on this one.. Thanks
It's hard to see how analysts could be snowed at least. As stated below, the main ingredient in Q sells at the rate of 150K scripts/week much cheaper as a generic, and the marketing costs for the 10K scripts of Q never seems to arise in any conversation. Arena may get 1/3, but it's pretty expensive to do marketing. It's almost like there is the opinion that Q costs nothing to market. Analysts must be counting on a pretty successful marketing campaign! If you can't dazzle them with brilliance, baffle them with BS!
There is really an amazing contrast in the balance sheet and income statements of the two companies. That is probably why the Credit Suisse analyst does not do an actual valuation on the two companies
Every Doctor knows about it already because Phen was approved by the FDA in 1956 and Top was approved in 1997. No doctors know what Lorc is. Their sales truly are pathetic considering they have been on market for a year and doctors have no resistance to scripting it. That's also why the doctor surveys are meaningless because less than 7% had even heard of Belviq and all were provided selective data by Cowen which favored Q.
bronson u dum azzs...unbelievable that anyone would blindly ask for ANY info on yahoo MB...especially an opinion about numerical hard info....i think they call it doing ur own due diligence.
Qsymia has been on the market for over one year. It was known by all obesity specialist prior to the launch. Belviq has only been on the market for 16 weeks and could not market or advertise prior to that time. . If you look at week 16 in both launches, Belviq is doing much better at this point.